An Overview of Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary thyroid cancer in patients aged 2 years and older.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory differentiated thyroid cancer.